A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

Hospital Authority, Hong Kong

Status

Completed

Conditions

Chronic Disease

Kidney Diseases

Cardiovascular Diseases

Treatments

Drug: erythropoietin

Study type

Interventional

Funder types

Other

Identifiers

NCT00563355

HARECCTR0500004

CRE2000.241

Details and patient eligibility

About

The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease

Enrollment

66 patients

Sex

All

Ages

Under 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
Patients below the age of 75

Exclusion criteria

Patients with valvular heart disease/congenital heart disease
Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
Patients with history of heart failure
Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
Patients with thalassemic trait or haemoglobinopathies
Patients with underlying haematological malignancies
Patients with active bleeding
Patients with uncorrected iron or other vitamins deficiencies
Patients with poor general condition